Skip to content
Open access

Quantitation of Spatial Proteoforms in Alzheimer’s Disease

Jul 2026 · bioRxiv · 0 citations · 85 references
Biology

TL;DR

Findings establish spatial proteoforms as essential units of pathogenic analysis and reveal disease-relevant signals invisible to bulk tissue approaches in Alzheimer's disease.

Abstract

Alzheimer’s disease (AD) pathogenesis involves complex, multifactorial changes to the brain proteome that conventional unfractionated analyses may obscure. Proteins frequently occupy multiple subcellular compartments as spatial proteoforms, yet the contribution of aberrant protein localization to AD pathogenesis remains poorly understood. To address this, we fractionated post-mortem human hippocampi from 13 AD and 14 non-AD individuals into four subcellular fractions and quantified 6,123 proteins by TMT-LC-MS. Although 75% of proteins were detected in more than one fraction, 78% of significant AD-associated alterations were restricted to a single fraction, demonstrating that subcellular localization is a primary determinant of disease vulnerability. Discordant abundance patterns between fractions revealed retromer complex mislocalization, nuclear transport dysfunction, and insoluble protein accumulation, with the endosomal-lysosomal and protein folding pathways most consistently perturbed. To examine how these perturbations evolve with disease progression, we applied the QUAD strategy to measure protein degradation in two fractions of APPswePS1delta9 mouse cortex at 2, 5, and 12 months. Degradation rates diverged between fractions and genotypes in an age-dependent manner, and cross-dataset comparison identified six proteins altered at the earliest pre-pathological timepoint, implicating vesicle transport and proteostasis disruption as initiating features of AD. These findings establish spatial proteoforms as essential units of pathogenic analysis and reveal disease-relevant signals invisible to bulk tissue approaches.

Read PDF

Similar papers

Contribution of G4 Structure to Alzheimer’s Disease and Tau Pathology

This dissertation explores the hypothesis that G4-forming nucleic acids represent a mechanistic link between cellular stress, RNA biology, and tau aggregation in AD and establishes G-quadruplexes as previously underappreciated regulators of tau biology and implicates RNA structure as an active contributor to AD pathoge...

L. Kallweit · 0 citations
Open access Aug 2026

Population-scale subcellular proteomics reveals intracellular remodelling across the Alzheimer’s disease-resilience spectrum

Comparative subcellular proteomics applied to dorsolateral prefrontal cortex from 75 individuals spanning the Alzheimer’s disease-resilience spectrum is developed, modelling protein localisation across disease.

Helen A. Jolly, Paula Seghers, Kaleah Balcomb et al. · 0 citations
Open access Jul 2026

Carbonyl stress primes the metastable aging brain for Alzheimer’s disease

Alzheimer’s disease (AD) is defined by amyloid-β (Aβ) plaques and tau tangles, yet the inflammation that comes with it is only partly localized where those lesions accumulate. Using spatial transcriptomics on 16 human hippocampal sections containing adjacent cortex, we found that plaques concentrated in grey matter, es...

Aurélien M. Badina, Eléonore Raveloson, I. Meister et al. · 0 citations
Open access

A proteomic approach to unravel neurodegeneration

The potential of proteomics to characterize the molecular complexity of AD and reveal interconnected changes across different levels of disease biology is demonstrated, supporting a view of AD as a progressive disruption of cellular and intercellular communication and emphasizing the need for multi-targeted approaches...

Evangelia Thanou · 0 citations
Open access Jul 2026

Retinal proteome changes mirror brain pathology and reveal synaptic and cytoskeletal dysfunction in Alzheimer’s disease

Visual dysfunction is increasingly recognized as an important feature of Alzheimer’s disease, and substantial retinal changes have been documented across multiple studies. Yet the molecular changes underlying retinal neurodegeneration and which retinal protein signatures best track cerebral pathology remain incompletel...

Jessica Santiago, Dovilė Pocevičiūtė, Teo Sällberg et al. · 0 citations
Open access Aug 2026

Alzheimers disease blood biomarkers reveal proteomic modules of disease progression

Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.

R. R. Butler, M. Brown, A. Weber et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.